BridgeBio Posts Q3 Revenue of US$353 Million With BBP-418 Decision Due 27 November

Aditi Sarkar

02 November 2026 11:34 PM AEDT

BridgeBio Posts Q3 Revenue of US$353 Million With BBP-418 Decision Due 27 November

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Total third-quarter 2026 Revenue reached US$353.2 million, up from US$120.7 million in the same quarter of 2025.
U.S. Attruby net product revenue climbed to US$253.2 million, rising about US$31 million from the preceding quarter.
Net loss narrowed to US$60.5 million from US$184.9 million, while net loss per share improved to US$0.42.
BridgeBio holds three FDA decision dates: BBP-418 in November 2026, infigratinib in February 2027 and encaleret in May 2027.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is heading into the last weeks of 2026 with its first approved medicine carrying most of its revenue and a US regulatory decision on its second product less than a month away.

On 29 October 2026, the rare-disease drug developer reported third-quarter revenue of US$353.2 million, close to three times the prior-year level, driven by Attruby (acoramidis), its treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). The company also reiterated a 27 November 2026 FDA target action date for BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

Attruby Carries the Revenue Line

U.S. Attruby net product revenue was US$253.2 million in Q3 2026, up US$145.2 million year on year and about US$31 million on the second quarter. Management attributed the growth to treatment-naive patients, with both the number of new starts and their share of new starts rising.

Royalty revenue, mainly tied to Beyonttra sales in the EU and Japan, rose to US$20.5 million from US$4.3 million. License and services revenue reached US$79.3 million, including a US$75.0 million sales milestone from Bayer recognized in the quarter. For the nine months to 30 September 2026, total revenue was US$791.4 million, against US$347.9 million a year earlier.

Operating Loss Shrinks as Launch Spending Grows

Total operating costs and expenses increased to US$364.8 million from US$265.9 million. Research and Development expense rose to US$143.5 million, while selling, general and administrative expense climbed to US$200.9 million. Even so, the loss from operations narrowed sharply to US$11.6 million from US$145.2 million.

The GAAP net loss was US$60.5 million. After US$26.3 million of preferred stock dividends and accretion, the net loss attributable to common stockholders was US$83.0 million, or US$0.42 per share, compared with US$0.95 per share a year earlier.

Cash, cash equivalents and marketable securities stood at US$1.54 billion on 30 September 2026, up from US$587.5 million at the end of 2025. During the first nine months of the year, BridgeBio issued US$632.5 million of 2033 notes and US$933.9 million of preferred stock and repurchased US$252.5 million of common stock. Management stated that its cash position fully funds its three launches and expansion indications.

Three FDA Decisions Lined Up Through May 2027

BBP-418 for LGMD2I/R9 has a PDUFA date of 27 November 2026 after its new drug application was accepted with Priority Review on 27 May 2026, and no advisory committee meeting is planned. The company has identified more than 500 US patients with the condition.

Oral infigratinib for achondroplasia has a PDUFA date of 4 February 2027, and encaleret for autosomal dominant hypocalcemia type 1 (ADH1) has a PDUFA date of 8 May 2027. Both are also under review in the EU, where the company sees potential approvals in the second half of 2027. A Phase 3 study of encaleret in chronic hypoparathyroidism has dosed its first participant, with topline data expected in early 2028.

FAQs

Q: What drove BridgeBio's third-quarter revenue?

A: U.S. Attruby net product revenue of US$253.2 million made up most of the US$353.2 million total, alongside royalty revenue and a US$75.0 million Bayer sales milestone.

Q: When is the FDA decision on BBP-418 expected?

A: The PDUFA target action date for BBP-418 in LGMD2I/R9 is 27 November 2026.

Q: How much cash did BridgeBio hold at the end of the quarter?

A: Cash, cash equivalents and marketable securities totaled US$1.54 billion on 30 September 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.